



References

1. Pham T, Fautrel B, Dernis E et al. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis : 2007 update. *Joint Bone Spine* 2007;74(6):638-46.
2. Pham T, Fautrel B, Gottenberg J-E et al. Rituximab (Mabthera®) therapy and safety management. *Joint Bone Spine* 2008;75(Suppl.1):S1-99.
3. Pham T, Claudepierre P, Constantin A et al. Abatacept therapy and safety management. *Joint Bone Spine* 2009;76(Suppl.1):S3-55.
4. Summary of Product Characteristics for tocilizumab. EMA 2009. <http://www.emea.europa.eu/>
5. Prise en charge thérapeutique du patient dyslipidémique. AFSSAPS 2005. <http://www.afssaps.fr/Infos-de-securite/Recommandations-de-bonne-pratique/Prise-en-charge-du-patient-dyslipidemique/>
6. Prise en charge des patients adultes atteints d'hypertension artérielle essentielle. HAS 2005. http://www.has-ante.fr/portail/upload/docs/application/pdf/hta_patient_adulte_synthese.pdf
7. Traitement médicamenteux du diabète de type 2 (actualisation). HAS 2006. http://www.has-sante.fr/portail/upload/docs/application/pdf/synthese_diabete-2006.pdf
8. Pham T, Gossec L, Constantin A et al. Cardiovascular risk and rheumatoid arthritis: clinical practice guide- lines based on published evidence and expert opinion. *Joint Bone Spine* 2006;73:379-87.
9. Méthodes d'évaluation du risque cardio-vasculaire global. ANAES 2004. http://www.has-sante.fr/portail/upload/docs/application/pdf/Risque_cardo_vasculaire_synth.pdf
10. Hippisley-Cox J, Coupland C, Vinogradova Y et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. *BMJ* 2008;336:1475-82.
11. van Vollenhoven R, Siri D, Furie R et al. Long-term safety and tolerability of tocilizumab treatment in patients with rheumatoid arthritis and mean treatment duration of 2.4 years (Concurrent Abstract Session). *Arthritis Rheum* 2009;60(Supplement):S731.
12. Genovese M, Smolen J, Emery P et al. Lipid and Inflammatory Biomarker Profiles in Patients Receiving Tocilizumab for Rheumatoid Arthritis: Analysis of Five Phase 3 Clinical Trials (Abstract). *Arthritis Rheum* 2008;58(Suppl):S531-2.
13. Genovese M, Smolen J, Emery P et al. Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis with Elevated Low Density Lipoprotein Cholesterol: Analysis of Five Phase 3 Clinical Trials (Abstract). *Arthritis Rheum* 2008;58(Suppl):S785-6.
14. Abeywardena MY, Leifert WR, Warnes KE et al. Cardiovascular biology of interleukin-6. *Curr Pharm Des* 2009;15:1809-21.
15. Danesh J, Kaptoge S, Mann AG et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. *PLoS Med* 2008;5:e78.
16. Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. *Rheumatology* 2009;48:11-22.
17. Nurmohamed MT. Cardiovascular risk in rheumatoid arthritis. *Autoimmun Rev* 2009;8:663-7.
18. Aviña-Zubieta JA, Choi HK, Sadatsafavi M et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. *Arthritis Rheum* 2008;59:1690-7.
19. Boyer J-F, Gourraud P-A, Cantagrel A, Constantin A. Evaluation de la prévalence des facteurs de risque cardiovasculaire classiques au cours de la polyarthrite rhumatoïde. *Rev Rhum* 2008;75:989.

20. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. *Ann Rheum Dis* 2009;68:460-9.
21. Hahn BH, Grossman J, Ansell BJ et al. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. *Arthritis Res Ther* 2008;10:213.
22. Panoulas VF, Douglas KM, Milionis HJ et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. *Rheumatology* 2007;46:1477-82.
23. John H, Hale ED, Treharne GJ, Kitas GD. Patient education on cardiovascular aspects of rheumatoid disease: an unmet need. *Rheumatology* 2007;46:1513-6.
24. van Halm VP, Peters MJ, Voskuyl AE et al. Rheumatoid arthritis *versus* diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. *Ann Rheum Dis* 2009;68:1395-400.
25. Boyer JF, Cantagrel A, Constantin A. Impact of traditional therapies and biologics on cardiovascular diseases in rheumatoid arthritis. *Curr Vasc Pharmacol* 2008;6:218-27.
26. Hamdulay SS, Mason JC. Disease-modifying anti-rheumatic drugs: do they reduce cardiac complications of RA? *Heart* 2009;95:1471-2.
27. Poole CD, Conway P, Currie CJ. An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice. *Rheumatology* 2009;48:78-82.
28. Omata Y, Nakamura I, Matsui T et al. Neutropenia induced by anti-interleukin-6 receptor antibody, tocilizumab. *Ann Rheum Dis* 2009;68(Suppl3):582.
29. Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. *Arthritis Rheum* 2004;50:1761-9.
30. Nishimoto N, Miyasaka N, Yamamoto K et al. Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody in monotherapy, in patients with rheumatoid arthritis (the STREAM Study) : evidence of safety and efficacy in a 5-year extension study. *Ann Rheum Dis* 2009;68:1580-4.
31. Maini RN, Taylor PC, Szechinski J et al. Double-Blind Randomized Controlled Clinical Trial of the Interleukin-6 Receptor Antagonist, Tocilizumab, in European Patients With Rheumatoid Arthritis Who Had an Incomplete Response to Methotrexate. *Arthritis Rheum* 2006;54:2817-29.
32. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of Interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebo-controlled, randomised trial. *Lancet* 2008;371:987-97.
33. Nishimoto N, Miyasaka N, Yamamoto K et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. *Mod Rheumatol* 2009;19:12-9.
34. Nishimoto N, Hashimoto J, Miyasaka N et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. *Ann Rheum Dis* 2007;66:1162-7.
35. Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. *Arthritis Rheum* 2008;58:2968-80.
36. Emery P, Keystone E, Tony H-P et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics : results from a 24-week multicentre randomised placebo controlled trial. *Ann Rheum Dis* 2008;67:1516-23.

37. Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy *versus* methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis : the AMBITION study. *Ann Rheum Dis* 2009 Mars 17 (Epub ahead of print).
38. Kremer J, Fleischmann RM, Saurigny D et al. Safety and tolerability of tocilizumab in combination with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX : 1-year results of the LITHE study. *EULAR* 2009, 10-13 juin, Copenhagen, Danemark. Abst. FRI0262.
39. Barclay S, Pol S, Mutimer D et al. The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting. *J Clin Virol* 2008;42:104-15.
40. Van Vollenhoven RF, Keystone E, Furie R et al. Gastrointestinal safety in patients with Rheumatoid Arthritis (RA) treated with tocilizumab in the Roche clinical trials database. *ACR* 2009, 17-21 October, Philadelphia, Pennsylvania. Pres. 1613.
41. Loomba R, Rowley A, Wesley R et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. *Ann Intern Med.* 2008;148:519-28.
42. EASL clinical practical guidelines. *J Hepatol* 2009;50:227-47.
43. Koike R, Harigai M, Atsumi T et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. *Mod Rheumatol* 2009;19:351-7.
44. Kremer J, Reed G, John AK, Onofrei A. Physician behaviour in response to liver enzyme elevations in Rheumatoid Arthritis patients receiving TNF- α inhibitors and/or methotrexate : analysis of the CORRONA registry database. *EULAR* 2009, 10-13 June, Copenhagen, Denmark. Abstract THU0557.
45. Kremer J, van Vollenhoven R, Ridley DJ et al. Relationship between patient characteristics and the development of serious infections in patients receiving tocilizumab: results from long-term extension studies with a follow-up duration of 1.5 years. *Arthritis Rheum* 2008;58(Suppl):S-783 (Abstract 1668).
46. Fleischmann R, Burgos-Vargas R, Ambs P et al. LITHE : tocilizumab inhibits radiographic progression and improves physical function in Rheumatoid Arthritis (RA) patients (Pts) at 2 Yrs with increasing clinical efficacy over time. *ACR* 2009, 17-21 October, Philadelphia, Pennsylvania. Pres. 637.
47. FDA. Food and Drug Administration.
(http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4371s1-02-Roche-core_files/frame.htm)
48. AFSSAPS. Prévention et prise en charge des tuberculoses survenant sous anti-TNF.
<http://www.agmed.sante.gouv.fr/html/10/tnf/reco.pdf>.
49. Matsui T, Komiya A, Nakayama H et al. Neutrophil CD 64 as an infection marker for RA patients treated with tocilizumab. *Ann Rheum Dis* 2009;68(suppl3):570 (Abstract SAT 0090).
50. Gabay C. Interleukin 6 and chronic inflammation. *Arthritis Res Ther* 2006;8 (Suppl. 2):53.
51. Smolen J, Baulieu AD, Dikranian A et al. Safety of Tocilizumab in patients with rheumatoid arthritis: pooled analysis of five phase 3 clinical trials. *Arthritis Rheum* 2008;58 (Suppl): S-784 (Abstract 1669).
52. van Vollenhoven R, Nishimoto N, Yamanaka H et al. Experience with mycobacterium tuberculosis infection reported in the tocilizumab worldwide RA safety database. *Ann Rheum Dis* 2009;68(suppl3):567 (Abstract SAT0081).
53. Ogawa J, Harigai M, Akashi T et al. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody. *Ann Rheum Dis* 2006;65:1667-9.
54. Nagashima T, Minota S. Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. *Rheumatology* 2008;47:1838-40.
55. De Bandt M, Saint-Marcoux B. Tocilizumab for multirefractory adult-onset Still's disease. *Ann Rheum Dis* 2009;68:153-4.

56. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics. *Cancer* 2007;110:1911-28.
57. Mumm JB, Oft M. Cytokine-based transformation of immune surveillance into tumor-promoting inflammation. *Oncogene* 2008;27:5913-9.
58. Rabau M, Kashtan H, Baron S et al. Inhibition of CT-26 murine adenocarcinoma growth in the rectum of mice treated with recombinant human interleukin-6. *J Immunother Emphasis Tumor Immunol* 1994;15:257-64.
59. Bihl M, Tamm M, Nauck M et al. Proliferation of human non-small-cell lung cancer cell lines: role of interleukin-6. *Am J Respir Cell Mol Biol* 1998;19:606-12.
60. Lan Q, Zheng T, Rothman N et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. *Blood* 2006;107:4101-8.
61. Theodoropoulos G, Papaconstantinou I, Felekouras E et al. Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. *World J Gastroenterol* 2006;12:5037-43.
62. Heikkila K, Ebrahim S, Lawlor DA. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. *Eur J Cancer* 2008;44:937-45.
63. Naugler WE, Sakurai T, Kim S et al. Gender disparity in liver cancer due to sex differences in MyD88- dependent IL-6 production. *Science* 2007;317:121-4.
64. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. *Trends Mol Med* 2008;14:109-19.
65. Maeda S, Kamata H, Luo JL et al. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. *Cell* 2005;121:977-90.
66. Garcia de G, Boyano D, Smith-Zubiaga I et al. Involvement of interleukin-6 in the biology and metastatic activity of B16F10 melanoma cells. *Eur Cytokine Netw* 1998;9:187-92.
67. Mouawad R, Rixe O, Meric JB et al. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. *Cytokines Cell Mol Ther* 2002;7:151-6.
68. Schuler M, Bruntsch U, Spath-Schwalbe E et al. Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II study. *Eur J Cancer* 1998;34:754-6.
69. Blay JY, Rossi JF, Wijdenes J et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. *Int J Cancer* 1997;72:424-30.
70. FDA. Actemra (tocilizumab) for Rheumatoid Arthritis. FDA Perspective. Arthritis Advisory Committee, July 29 2008.
71. Laine L, Connors LG, Reicin A et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. *Gastroenterology* 2003;124:288-92.
72. Mpofo S, Mpofo CM, Hutchinson D et al. Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions. *Ann Rheum Dis* 2004;63:588-90.
73. Hutchinson D, Lynch M. Sigmoid diverticular abscess perforation in 2 patients with rheumatoid arthritis treated with high dose corticosteroids. A cautionary tale. *J Rheumatol* 2001;28:1935-6.
74. Durieux S, Rozenberg S, Bourgeois P. [Complications of colonic diverticular disease during rheumatoid polyarthritis: 7 cases]. *Rev Med Interne* 1999;20:50-3.
75. Myllykangas-Luosujärvi R, Aho K, Isomäki H. Death attributed to antirheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died. *J Rheumatol* 1995;22:2214-7.
76. Myllykangas-Luosujärvi R. Diverticulosis - a primary cause of life-threatening complications in rheumatoid arthritis. *Clin Exp Rheumatol* 1995;13:79-82.
77. Recommendations. *Gastroentérol Clin Biol* 2007;31(Suppl.1):9-22. http://www.snfge.asso.fr/01-Bibliotheque/0D-Pratiques-cliniques/reco_diverticulite-2007.pdf.

78. Gallucci RM, Sugawara T, Yucesoy B et al. Interleukin-6 treatment augments cutaneous wound healing in immunosuppressed mice. *J Interferon Cytokine Res* 2001;21:603-9.
79. Lin ZQ, Kondo T, Ishida Y et al. Essential involvement of Il-6 in the skin wound-healing process as evidenced by delayed wound healing in Il-6 deficient mice. *J Leukoc Biol* 2003;73:713-21.
80. Hirao M, Hashimoto J, Tsuboi H et al. Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab. *Ann Rheum Dis* 2009;68:654-7.
81. Martin C, Viviand X, Gouin F et al. Antibio prophylaxie en chirurgie. In Bergogne-Berezin E, Dellamonica P. *Antibiothérapie en pratique clinique*. Abrégés Masson, 2ème édition, Paris 1999.
82. Tong DC, Rothwell BR et al. Antibiotic prophylaxis in dentistry: a review and practice recommendations. *JADA* 2000;131:366-74.
83. CRAT : Centre de Référence sur les Agents Tératogènes, Hôpital Armand Trousseau, Paris, AP-HP. <http://lecrat.org>
84. Ravikumar R, Anolik J, Looney RJ. Vaccine responses in patients with rheumatoid arthritis. *Curr Rheumatol Rep* 2007;9:407-15.
85. Tsuru T, Suzaki M, Yoshio N et al. Immune response to influenza vaccine in patients during the treatment with tocilizumab – comparison with conventional DMARDs and TNF inhibitors. *Ann Rheum Dis* 2008;67 (Suppl 2):339.
86. Tsuru T, Terao K, Suzaki M et al. Immune Response to Pneumococcal Vaccine in Patients with Rheumatoid Arthritis under IL-6 Receptor Inhibition Therapy with Tocilizumab. *Arthritis Rheum* 2007;56(suppl 9):S423.
87. Gartlehner G, Hansen RA, Jonas BL, et al. Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. *Clin Rheumatol*. 2008;27:67-76.
88. Ravelli A, Martini A. Juvenile Idiopathic Arthritis. *Lancet* 2007;369:767-78.
89. Haines KA. Juvenile Idiopathic Arthritis Therapies in the 21st Century. *Bull NYU Hosp Jt Dis*. 2007;65:205-11.
90. Oen K, Malleson PN, Cabral DA et al. Disease course and outcome of juvenile rheumatoid arthritis in a multicentre cohort. *J Rheumatol* 2002;29:1989-99.
91. Recommandations HAS 2009.
92. Woo P, Wilkinson N, Prieur A-M et al. Open-label phase II trial of single, ascending doses of MRA in caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. *Arthritis Res & Ther*. 2005;7:R1281-R1288.
93. Yokota S, Miyamae T, Imagawa T et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. *Arthritis Rheum* 2005;52:818-25.
94. Yokota S, Imagawa T, Mori M et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. *Lancet* 2008;371:998-1006.
95. Inaba Y, Aoki C, Ozawa R et al. Radiologic evaluation of large joints during tocilizumab treatment in children with systemic juvenile idiopathic arthritis [abstract]. *Ann Rheum Dis* 2009;68(Suppl3):720.
96. Woo P, Southwood TR, Prieur AM et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. *Arthritis Rheum* 2000;43:1849-57.
97. Laxer RM, Schneider R: Systemic-onset juvenile chronic arthritis. In *Oxford Textbook of Rheumatology* Edited by: Isenberg DA, Maddison PJ, Woo P, Glass DN, Breedveld FC. Oxford: Oxford University Press;2004:798-810.
98. Quartier P, Taupin P, Bourdeaut F et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. *Arthritis Rheum* 2003;48:1093-101.

99. Gattorno M, Piccini A, Lasigliè L et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. *Arthritis Rheum* 2008;58:1505-15.
100. Yokota S, Miyamae T, Imagawa T et al. Clinical study of tocilizumab in children with systemic onset juvenile idiopathic arthritis. *Clin Rev Allergy Immunol*. 2005;28:231-8.
101. Urakami T, Manki A, Inoue T et al. Clinical significance of decreased serum concentration of cartilage oligomeric matrix protein in systemic juvenile idiopathic arthritis. *J Rheumatol*. 2006;33:996-1000.
102. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. *Nat Clin Pract Rheumatol* 2006;2:619-26.
103. Imagawa T, Takei S, Kawano Y et al. Efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in subjects with polyarticular or oligoarticular onset juvenile idiopathic arthritis [abstract]. *Arthritis Rheum* 2006;54:168.
104. Aoki C, Inaba Y, Ozawa R et al. Effects of tocilizumab on radiological findings in polyarticular juvenile idiopathic arthritis. *Ann Rheum Dis* 2009;68(Suppl3):118.
105. Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. *Arthritis Rheum* 2006;54:2997-3000.
106. De Benedetti F, Massa M, Robbioni P et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. *Arthritis Rheum* 1991;34:1158-63.
107. Prieur AM, Roux-Lombard P, Dayer JM. Dynamics of fever and the cytokine network in systemic juvenile arthritis. *Rev Rheum Engl* 1996;63:163-70.
108. De Benedetti F. Targeting interleukin-6 in pediatric rheumatic diseases. *Curr Opin Rheumatol* 2009;21:DOI:10.1097/BOR.0b013e32832f1445.
109. De Benedetti F, Alonzi T, Moretta A et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I: a model for stunted growth in children with chronic inflammation. *J Clin Invest* 1997;99:643-50.
110. Nakajima S, Naruto T, Miyamae T et al. Interleukin-6 inhibits early differentiation of ATDC5 chondrogenic progenitor cells. *Cytokine* 2009;47:91-7.
111. Giannini EH, Ruperto N, Ravelli A et al. Preliminary definition of improvement in juvenile arthritis. *Arthritis Rheum* 1997;40:1202-9.
112. de Jager W, Hoppenreijns EPAH, Wulffraat NM et al. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. *Ann Rheum Dis* 2007;66:589-98.
113. Peake NJ, Khawaja K, Myers A et al. Interleukin-6 signaling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor. *Rheumatology* 2006;45:1485-89.
114. Nishimoto N, Kanakura Y, Aozasa K et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castelman disease. *Blood* 2005;106:2627-32.
115. Nishimoto N. Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan. *Clin Rev Allergy Immunol*. 2005;28:221-30.
116. Kanda J, Kawakawa H, Yamaji Y et al. Reversible cardiomyopathy associated with Multicentric Castleman disease: successful treatment with tocilizumab, an anti-interleukin 6 receptor antibody. *Int J Hematol* 2007;85:207-11.
117. Nishimoto N, Terao K, Mima T et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. *Blood* 2008;112:3959-64.
118. Iwamoto M, Nara H, Hirata D et al. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. *Arthritis Rheum* 2002;46:3388-9.

119. Nakahara H, Mima T, Yoshio-Hoshino N et al. A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years. *Mod Rheumatol* 2009;19:69-72.
120. Matsumoto K, Nagashima T, Takatori S et al. Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab. *Clin Rheumatol* 2009;28:485-7.
121. Puéchal X, De Bandt M, Berthelot JM et al. Efficacy and safety of tocilizumab in refractory adult Still's disease: a case series: submitted.
122. Scheinberg MA, Chapira E, Fernandes ML, Hubscher O. Interleukin 6: a possible marker of disease activity in adult onset Still's disease. *Clin Exp Rheumatol* 1996;14:653-5.
123. Hoshino T, Ohta A, Yang D et al. Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor- alpha levels in patients with adult Still's disease. *J Rheumatol* 1998;25:396-8.
124. Fujii T, Nojima T, Yasuoka H et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. *Rheumatology* 2001;40:1398-1404.
125. Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. *J Rheumatol* 2004;31:2189-98.
126. Tutuncu ZN, Bilgie A, Kennedy LG, Calin A. Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis. *Ann Rheum Dis* 1994;53:425-6.
127. Bal A, Unlu E, Bahar G, et al. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. *Clin Rheumatol* 2007;26:211-5.
128. Gratacós J, Collado A, Filella X et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. *Br J Rheumatol* 1994;33:927-31.
129. Park MC, Lee SW, Choi ST et al. Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. *Scand J Rheumatol* 2007;36:101-6.
130. Claudepierre P, Rymer JC, Authier FJ et al. A relationship between TGF-beta 1 or IL-6 plasma levels and clinical features of spondyloarthropathies. *Br J Rheumatol* 1997;36:400-1.
131. Falkenbach A, Herold M. In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility. *Rheumatol Int* 1998;18:103-6.
132. Wendling D, Racadot E, Augé B et al. Soluble intercellular adhesion molecule 1 in spondylarthropathies. *Clin Rheumatol* 1998;17:202-4.
133. Falkenbach A, Herold M, Wigand R. Interleukin-6 serum concentration in ankylosing spondylitis: a reliable predictor of disease progression in the subsequent year? *Rheumatol Int* 2000;19:149-51.
134. François RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. *Ann Rheum Dis* 2006;65:713-20.
135. Collado-Escobar MD, Nieto A, Matarán L et al. Interleukin 6 gene promoter polymorphism is not associated with ankylosing spondylitis. *J Rheumatol* 2000;27:1461-3.
136. Wendling D, Racadot E, Toussiroit E, Wijdenes J. Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy. *Br J Rheumatol* 1996;35:1330.